NEW YORK – Oxford Nanopore Technologies and Wasatch BioLabs (WBL) said Friday that they are collaborating to develop direct whole-methylome sequencing (dWMS).

纽约-牛津纳米孔技术公司和Wasatch BioLabs（WBL）周五表示，他们正在合作开发直接全甲基测序（dWMS）。

Based on WBL's existing methylation assays and Oxford Nanopore's sequencing technology and expertise, the companies are developing an approach that they believe will address the limitations of existing DNA methylation analysis methods. 'These products are poised to redefine the standard for epigenetic research and revolutionize the field,' WBL CEO and Cofounder Chad Pollard said in a statement..

基于WBL现有的甲基化分析和牛津纳米孔的测序技术和专业知识，这些公司正在开发一种方法，他们认为这种方法将解决现有DNA甲基化分析方法的局限性。”WBL首席执行官兼联合创始人查德·波拉德（ChadPollard）在一份声明中表示，这些产品有望重新定义表观遗传学研究的标准，并彻底改变该领域。。

'Together we will codevelop products that will replace conventional technologies such as sequencing arrays and bisulfite sequencing and reshape how methylation is incorporated into clinical research and diagnostics,' said Kathleen Barnes, senior VP of population health and precision medicine at Oxford Nanopore..

牛津纳米孔大学（Oxford Nanopore）人口健康与精准医学高级副总裁凯瑟琳·巴恩斯（KathleenBarnes）说：“我们将共同开发替代测序阵列和亚硫酸氢盐测序等传统技术的产品，并重塑甲基化如何纳入临床研究和诊断。”。。

Financial and other terms of the agreement were not disclosed.

协议的财务和其他条款没有披露。

Earlier this year, Salt Lake City-based WBL, a spinout from Brigham Young University, launched its first commercial offering, a targeted DNA methylation nanopore sequencing service that is based on proprietary molecular enrichment technology. At that time, the firms were not yet collaborating.

今年早些时候，位于盐湖城的WBL（Brigham Young University的分支机构）推出了其第一个商业产品，这是一种基于专有分子富集技术的靶向DNA甲基化纳米孔测序服务。当时，这些公司还没有合作。